Abstract: An enzyme for reducing cystine to cysteine is a fusion protein that includes the protein activities of thioredoxin (protein i) having KEGG database number EC 1.8.4.8 or EC 1.8.4.10 and thioredoxin reductase (protein ii) having KEGG database number EC 1.8.1.9. The thioredoxin (protein i) is the protein activity of thioredoxin 1 from E. coli and the thioredoxin reductase (protein ii) is the protein activity of the thioredoxin reductase from E. coli. The activity of the fusion protein is at least 100% of the activity of a mixture of the same but unfused individual proteins i and ii. The fusion protein has the enzyme activity to reduce cystine to cysteine. The coding sequences (cds) responsible for the activity of protein i and ii has been fused.

Abstract: The present invention concerns a method of producing and enantiomerically pure alpha-ionone. Further, the invention concerns a nucleic acid that comprises a sequence that encodes a lycopene-epsilon-cyclase (EC), a lycopene-epsilon-cyclase (EC), plasmids, which encode components of the alpha-ionone biosynthesis and a microorganism that contains heterologous nucleotide sequences which encode the enzymes geranylgeranyl-diphosphate-synthase, isopentenyl-diphosphate-isomerase (IPI), phytoene desaturase-dehydrogenase (crtI), phytoene synthase (crtB), lycopene-epsilon-cyclase (EC) and carotenoid-cleavage-dioxygenase (CCD1). Further, the invention concerns a method of producing highly pure epsilon-carotene.

Abstract: The invention relates to providing both fermentative and biotechnological methods for producing 3,4-methylized cinnamic acids, 3,4-methylized cinnamic acid esters, 3,4-dimethoxyphenethylamine, and 4-methylized cinnamic acid amides using a 4?-O-methyltransferase, optionally in combination with further enzymes, wherein the enzymes are selected by means of metabolic engineering and operation have been adapted by targeted optimization, and compositions obtained by means of the method. The invention further relates to vector systems, recombinant microorganisms or fungi, and specific nucleic acid segments and polypeptides.

Abstract: The present invention concerns a method of producing and enantiomerically pure alpha-ionone. Further, the invention concerns a nucleic acid that comprises a sequence that encodes a lycopene-epsilon-cyclase (EC), a lycopene-epsilon-cyclase (EC), plasmids, which encode components of the alpha-ionone biosynthesis and a microorganism that contains heterologous nucleotide sequences which encode the enzymes geranylgeranyl-diphosphate-synthase, isopentenyl-diphosphate-isomerase (IPI), phytoene desaturase-dehydrogenase (crtI), phytoene synthase (crtB), lycopene-epsilon-cyclase (EC) and carotenoid-cleavage-dioxygenase (CCD1). Further, the invention concerns a method of producing highly pure epsilon-carotene.

Abstract: The invention relates to providing both fermentative and biotechnological methods for producing 3,4-methylized cinnamic acids, 3,4-methylized cinnamic acid esters, 3,4-dimethoxyphenethylamine, and 4-methylized cinnamic acid amides using a 4?-O-methyltransferase, optionally in combination with further enzymes, wherein the enzymes are selected by means of metabolic engineering and operation have been adapted by targeted optimization, and compositions obtained by means of the method. The invention further relates to vector systems, recombinant microorganisms or fungi, and specific nucleic acid segments and polypeptides.

Abstract: The present invention relates to a cell, which has been genetically modified relative to its wild type, so that in comparison with its wild type it is able to produce more ?-aminocarboxylic acids, more ?-aminocarboxylic acid esters or more lactams derived from ?-aminocarboxylic acids, starting from carboxylic acids or carboxylic acid esters. Furthermore, the present invention relates to a method for the production of a genetically modified cell, the cells obtainable by this method, a method for the production of ?-aminocarboxylic acids, of ?-aminocarboxylic acid esters or of lactams derived from ?-aminocarboxylic acids, the ?-aminocarboxylic acids, ?-aminocarboxylic acid esters or lactams derived from ?-aminocarboxylic acids obtainable by this method, a method for the production of polyamides based on ?-aminocarboxylic acids or based on lactams and the polyamides obtainable by this method.

Abstract: The present invention relates to a cell, which has been genetically modified relative to its wild type, so that in comparison with its wild type it is able to produce more ?-aminocarboxylic acids, more ?-aminocarboxylic acid esters or more lactams derived from ?-aminocarboxylic acids, starting from carboxylic acids or carboxylic acid esters. Furthermore, the present invention relates to a method for the production of a genetically modified cell, the cells obtainable by this method, a method for the production of ?-aminocarboxylic acids, of ?-aminocarboxylic acid esters or of lactams derived from ?-aminocarboxylic acids, the ?-aminocarboxylic acids, ?-aminocarboxylic acid esters or lactams derived from ?-aminocarboxylic acids obtainable by this method, a method for the production of polyamides based on ?-aminocarboxylic acids or based on lactams and the polyamides obtainable by this method.

Abstract: Transgenic pathogen-resistant organism whose genome contains at least two different genes under the control of active promoters with pathogen-inhibiting action. This organism is distinguished by a synergistic pathogen-inhibiting action. This action is evident particularly when the genes code for the gene products chitinase (ChiS, ChiG), glucanase (GluG), protein synthesis inhibitor (PSI) and antifungal protein (AFP).

Abstract: Described are a method of producing pathogen-resistant plants in which a protein-synthesis inhibitor gene or a fusion product of the protein-synthesis inhibitor gene or of the protein-synthesis inhibitor protein with ligands permitting specific attachment to cells is introduced into the genotype of plants under the control of an active promotor, and the use of the protein-synthesis inhibitor protein obtained by introducing the protein-synthesis inhibitor gene into the bacterial overproducers for making pharmaceutical preparations.

Abstract: Transgenic pathogen-resistant organism whose genome contains at least two different genes under the control of active promoters with pathogen-inhibiting action. This organism is distinguished by a synergistic pathogen-inhibiting action. This action is evident particularly when the genes code for the gene products chitinese (ChiS, ChiG), glucanase (GluG), protein synthesis inhibitor (PSI) and antifungal protein (AFR).

Abstract: Transgenic pathogen-resistant organism whose genome contains at least two different genes under the control of active promoters with pathogen-inhibiting action. This organism is distinguished by a synergistic pathogen-inhibiting action. This action is evident particularly when the genes code for the gene products chitinase (ChiS, ChiG), glucanase (GluG), protein synthesis inhibitor (PSI) and antifungal protein (AFP).

Abstract: Transgenic pathogen-resistant organism whose genome contains at least two different genes under the control of active promoters with pathogen-inhibiting action. This organism is distinguished by a synergistic pathogen-inhibiting action. This action is evident particularly when the genes code for the gene products chitinase (ChiS, ChiG), glucanase (GluG), protein synthesis inhibitor (PSI) and antifungal protein (AFP).

Abstract: Described are a method of producing pathogen-resistant plants in which a protein-synthesis inhibitor gene or a fusion product of the protein-synthesis inhibitor gene or of the protein-synthesis inhibitor protein with ligands permitting specific attachment to cells is introduced into the genotype of plants under the control of an active promotor, and the use of the protein-synthesis inhibitor protein obtained by introducing the protein-synthesis inhibitor gene into the bacterial overproducers for making pharmaceutical preparations.

Abstract: Transgenic pathogen-resistant organism whose genome contains at least two different genes under the control of active promoters with pathogen-inhibiting action. This organism is distinguished by a synergistic pathogen-inhibiting action. This action is evident particularly when the genes code for the gene products chitinase (ChiS, ChiG), glucanase (GluG), protein synthesis inhibitor (PSI) and antifungal protein (AFP).